Hereditary Angioedema Therapy: Kallikrein Inhibition and Bradykinin Receptor Antagonism

World Allergy Organization Journal

Volumn 3, Issue , 2010, Pages S34-S38

  Riedl, Marc ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

contact system; ecallantide; HAE; icatibant

Indexed keywords

BRADYKININ ANTAGONIST; BRADYKININ B2 RECEPTOR; ECALLANTIDE; ICATIBANT; KALLIKREIN; KALLIKREIN INHIBITOR;

ACUTE DISEASE; ANGIONEUROTIC EDEMA; CONFERENCE PAPER; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERANCE; ENZYME ACTIVITY; ENZYME INHIBITION; HEALTH CARE PLANNING; HUMAN; MULTICENTER STUDY (TOPIC); NONHUMAN; PATIENT-REPORTED OUTCOME; PHASE 3 CLINICAL TRIAL (TOPIC); PHASE 4 CLINICAL TRIAL (TOPIC); PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECEPTOR BLOCKING; SIDE EFFECT; VISUAL ANALOG SCALE;

EID: 85014224892     PISSN: None     EISSN: 19394551     Source Type: Journal    
DOI: 10.1186/1939-4551-3-S3-S34     Document Type: Conference Paper

References (27)

1. Cugno M, Zanichelli A, Foieni F, Caccia S, Cicardi M: C1-inhibitor deficiency and angioedema: molecular mechanisms and clinical progress. Trends Mol Med. 2009, 15: 69-78. 10.1016/j.molmed.2008.12.001.
2. Zuraw BL, Christiansen SC: Pathogenesis and laboratory diagnosis of hereditary angioedema. Allergy Asthma Proc. 2009, 30: 487-492. 10.2500/aap.2009.30.3277.
3. Weiss R, Silverberg M, Kaplan AP: The effect of C1 inhibitor upon Hageman factor autoactivation. Blood. 1986, 68: 239-243.
4. Kaplan AP, Joseph K, Silverberg M: Pathways for bradykinin formation and inflammatory disease. J Allergy Clin Immunol. 2002, 109: 195-209. 10.1067/mai.2002.121316.
5. Fields T, Ghebrehiwet B, Kaplan AP: Kinin formation in hereditary angioedema plasma: evidence against kinin derivation from C2 and in support of «spontaneous» formation of bradykinin. J Allergy Clin Immunol. 1983, 72: 54-60. 10.1016/0091-6749(83)90052-0.
6. Han ED, MacFarlane RC, Mulligan AN, Scafidi J, Davis AE: 3rd. Increased vascular permeability in C1 inhibitor-deficient mice mediated by the bradykinin type 2 receptor. J Clin Invest. 2002, 109: 1057-1063.
7. Nussberger J, Cugno M, Cicardi M, Cicardi M, Agostoni A: Local bradykinin generation in hereditary angioedema. J Allergy Clin Immunol. 1999, 104: 1321-1322. 10.1016/S0091-6749(99)70030-8.
8. Fernando LP, Natesan S, Joseph K, Kaplan AP: High molecular weight kininogen and factor XII binding to endothelial cells and astrocytes. Thromb Haemost. 2003, 90: 787-795.
9. Joseph K, Ghebrehiwet B, Kaplan AP: Cytokeratin 1 and gC1qR mediate high molecular weight kininogen binding to endothelial cells. Clin Immunol. 1999, 92: 246-255. 10.1006/clim.1999.4753.
10. Joseph K, Tholanikunnel BG, Ghebrehiwet B, Kaplan AP: Interaction of high molecular weight kininogen binding proteins on endothelial cells. Thromb Haemostasis. 2004, 91: 61-70.
11. Schmaier AH: Assembly, activation, and physiologic influence of the plasma kallikrein/kinin system. Int Immunopharmacol. 2008, 8: 161-165. 10.1016/j.intimp.2007.08.022.
12. Zhao Y, Qui Q, Mahdi F, Shariat-Madar Z, Rojkjaer R, Schmaier AH: Assembly and activation of HK-PK complex on endothelial cells results in bradykinin liberation and NO formation. Am J Physiol. 2001, 280: 1821-1829.
13. Bernstein JA, Qazi M: Ecallantide: its pharmacology, pharmacokinetics, clinical efficacy and tolerability. Expert Rev Clin Immunol. 2010, 6: 29-39. 10.1586/eci.09.60.
14. Vernon MK, Rentz AM, Wyrwich KW, White MV, Grienenberger A: Psychometric validation of two patient-reported outcome measures to assess symptom severity and changes in symptoms in hereditary angioedema. Qual Life Res. 2009, 18: 929-939. 10.1007/s11136-009-9509-8.
15. ® (ecallantide) For Acute Attacks of Hereditary Angioedema. Available at: http://www.fda.gov/ohrms/dockets/AC/09/briefing/2009-4413b1-03-Dyax.pdf. 2010, Accessed May 22
16. Horn PT, Li HH, Pullman WE: Hypersensitivity reactions following ecallantide treatment for acute attacks of HAE. Presented at the American Academy of Allergy, Asthma, and Immunology. 2010, New Orleans
17. [No authors listed] Icatibant: HOE 140, JE 049, JE049. Drugs R D. 2004, 5: 343-348.
18. European Medicines Agency: CHMP Assessment Report For Firazyr http://www.ema.europa.eu/humandocs/PDFs/EPAR/firazyr/H-899-en6.pdf. 2010, Accessed May 22
19. Craig T, Riedl M, Dykewicz MS, et al: When is prophylaxis for hereditary angioedema necessary?. Ann Allergy Asthma Immunol. 2009, 102: 366-372. 10.1016/S1081-1206(10)60506-6.
20. U.S Food and Drug Administration: CINRYZE (C1 Inhibitor) for routine prophylaxis against HAE attacks. Final clinical review Available at: http://www.fda.gov/downloads/BiologicsBloodVaccines/BloodBloodProducts/ApprovedProducts/LicensedProductsBLAs/FractionatedPlasmaProducts/ucm094092.pdf. 2010, Accessed May 22
21. Zuraw B, Yasothan U, Kirkpatrick P: Ecallantide. Nat Rev Drug Discov. 2010, 9: 189-190. 10.1038/nrd3125.
22. Craig TJ, Levy RJ, Wasserman RL, Bewtra AK, Hurewitz D: Efficacy of human C1 esterase inhibitor concentrate compared with placebo in acute hereditary angioedema attacks. J Allergy Clin Immunol. 2009, 124: 801-808. 10.1016/j.jaci.2009.07.017.
23. De Vries S: Pharming: Bio-Europe 2009. Available at: http://www.pharming.com/index.php?act=dl&file=bio-europe-vienna-03-nov-2009. 2010, pdf Accessed June 4
24. Longhurst H: Rhucin, a recombinant C1 inhibitor for the treatment of hereditary angioedema and cerebral ischemia. Curr Opin Investig Drugs. 2008, 9: 310-323.
25. Levi M, Choi G, Picavet C, Hack CE: Self-administration of C1inhibitor concentrate in patients with hereditary or acquired angioedema caused by C1-inhibitor deficiency. J Allergy Clin Immunol. 2006, 117: 904-908. 10.1016/j.jaci.2006.01.002.
26. Bygum A, Andersen KE, Mikkelsen CS: Self-administration of intravenous C1-inhibitor therapy for hereditary angioedema and associated quality of life benefits. Eur J Dermatol. 2009, 19: 147-151.
27. Banerji A, Sloane DE, Sheffer AL: Hereditary angioedema: a current state-of-the-art review, V: attenuated androgens for the treatment of hereditary angioedema. Ann Allergy Asthma Immunol. 2008, 100: S19-S22. 10.1016/S1081-1206(10)60582-0.